Overview
Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
Status:
No longer available
No longer available
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Imatinib Mesylate
Criteria
Inclusion Criteria:- Five patients who are on treatment of imatinib and deriving clinical benefit after
CAMN107DBR01 study termination and written informed consent obtained.
Exclusion Criteria:
- N/A.